Sully.ai vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF healthcare AutonomousOS automating clinical documentation and prior auth for hospitals; YC $30.5M Sequoia Scout/AUM Ventures Series A Jan 2025 competing with Nuance DAX and Abridge for AI-powered physician workflow automation.
About
Sully.ai is a San Francisco-based healthcare AI company — backed by Y Combinator with $30.5 to $32.1 million raised including a $21.83 million Series A in January 2025 from AUM Ventures, Leonis Capital, SemperVirens VC, and Sequoia Scout Fund — providing hospitals, physician practices, and health systems with an AutonomousOS platform that automates clinical documentation (ambient AI scribing that generates SOAP notes from patient-physician conversations), administrative workflows (prior authorization processing, insurance eligibility verification, scheduling automation), and revenue cycle management tasks that consume 30-40% of physician time and hospital administrative labor. Founded in 2023 by Ahmed Nasser and Ahmed Omar, Sully.ai has 49 employees and serves healthcare providers globally with AI agents that autonomously execute multi-step clinical and administrative processes without requiring physician or staff intervention.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.